TY - JOUR T1 - Targeted Identification of Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics JF - medRxiv DO - 10.1101/2022.07.25.22276982 SP - 2022.07.25.22276982 AU - Amy E. Campbell AU - Jamshid Arjomand AU - Oliver D. King AU - Rabi Tawil AU - Sujatha Jagannathan Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/26/2022.07.25.22276982.abstract N2 - Background Facioscapulohumeral muscular dystrophy (FSHD) is a progressive myopathy caused by misexpression of the double homeobox 4 (DUX4) embryonic transcription factor in skeletal muscle. Identifying quantitative and minimally invasive FSHD biomarkers to report on DUX4 activity will significantly accelerate therapeutic development.Objective The goal of this study was to analyze secreted proteins induced by DUX4 in order to identify potential blood-based molecular FSHD biomarkers.Methods We used high-throughput, multiplex immunoassays from Olink Proteomics to measure the level of several hundred proteins, including several DUX4-induced genes, in a cellular myoblast model of FSHD, in FSHD patient-derived myotube cell cultures, and in serum from individuals with FSHD.Results Placental alkaline phosphatase (ALPP) levels correlated with DUX4 expression in both cell-based FSHD systems but did not distinguish FSHD patient serum from healthy controls.Conclusions ALPP, as measured with the Olink Proteomics platform, is not a promising FSHD serum biomarker candidate but could be utilized to evaluate DUX4 activity in discovery research efforts.Competing Interest StatementJ.A. is the Chief Science Officer of the FSHD Society.Funding StatementThis study was funded by the FSHD Society (S.J. and A.E.C.), the Geraldi Norton Foundation (S.J. and A.E.C.), NIH 5P50HD060848-15 Wellstone Center for FSHD (O.D.K.), and the RNA Bioscience Initiative at the University of Colorado Anschutz Medical Campus (S.J.). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Subjects Review Board of the University of Rochester Office for Human Subject Protection gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -